Welcome to our dedicated page for Revolution Medicines SEC filings (Ticker: RVMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Revolution Medicines, Inc. (RVMD) provides access to the company’s official regulatory documents filed with the U.S. Securities and Exchange Commission. As a Nasdaq-listed late-stage clinical oncology company, Revolution Medicines uses these filings to report on its financial condition, clinical and regulatory milestones, and significant corporate agreements related to its RAS(ON) inhibitor pipeline.
Investors reviewing RVMD’s filings will find current reports on Form 8-K that describe material events such as clinical data updates, FDA designations and strategic financings. For example, the company has filed 8-Ks detailing Breakthrough Therapy Designation and a Commissioner’s National Priority Voucher for daraxonrasib, pipeline updates in pancreatic ductal adenocarcinoma and non-small cell lung cancer, and a Royalty Purchase Agreement with Royalty Pharma covering potential future net product sales of daraxonrasib and zoldonrasib.
Other 8-K filings discuss term loan facilities linked to regulatory approvals and sales milestones, leadership changes at the board and executive levels, and the listing of Revolution Medicines’ common stock (RVMD) and warrants (RVMDW) on The Nasdaq Stock Market LLC. Periodic filings such as Forms 10-Q and 10-K, referenced in the company’s forward-looking statements, provide more comprehensive discussions of risk factors, research and development activities, and overall business strategy.
On Stock Titan, these SEC filings are presented with real-time updates from EDGAR and AI-powered summaries that highlight key points, such as how financing agreements relate to daraxonrasib and zoldonrasib, or what new clinical or regulatory information is disclosed. Users can quickly identify items related to quarterly results (10-Q), annual reports (10-K), and current reports (8-K), as well as monitor registered securities like RVMD and RVMDW.
This page helps readers understand how Revolution Medicines reports on its RAS(ON) inhibitor programs, financial position and significant corporate events through its SEC disclosures, with AI tools simplifying navigation of complex oncology and financing information.
Revolution Medicines’ general counsel, Jeff Cislini, reported a small, pre-planned stock sale. On January 21, 2026, he sold 908 shares of Revolution Medicines common stock at $115.60 per share under a Rule 10b5-1 trading plan adopted on March 13, 2025. After this sale, he beneficially owned 46,976 shares, which include 38,769 restricted stock units that typically vest over time.
Revolution Medicines shareholder Jeffrey Todd Cislini has filed a notice to sell common stock. The filing covers a planned sale of 908 common shares through Morgan Stanley Smith Barney LLC on or around 01/21/2026 on the NASDAQ market. These shares were acquired as restricted stock units from the issuer on 12/15/2025, and the block has an aggregate market value of $105,527.76.
The notice states that Revolution Medicines had 193,319,805 common shares outstanding at the time referenced. Over the prior three months, Cislini sold 2,688 common shares on 12/16/2025 for $206,483.83 and 13,388 common shares on 11/18/2025 for $939,008.57, with the larger transaction noted as Rule 10b5-1 sales. By signing, the seller represents they are not aware of undisclosed material adverse information about the company’s operations.
Revolution Medicines, Inc. Chief Operating Officer Margaret A. Horn reported a series of option exercises and share sales on January 7, 2026. She exercised stock options for 51,406 shares of common stock at $42.45 per share and 23,594 shares at $29.80 per share, then sold 53,096, 20,204 and 1,700 shares of common stock at weighted average prices of $100.0164, $101.7928 and $102.90, respectively. The transactions were made under a Rule 10b5-1 trading plan adopted on March 7, 2025. After these trades, she directly beneficially owned 141,053 shares of common stock, which include 61,226 restricted stock units, and held remaining stock options covering 1,094 and 119,906 shares with vesting described in the filing.
Revolution Medicines Chief Financial Officer Jack Anders reported an exercise and sale of company stock. On January 7, 2026, he exercised a stock option for 10,000 shares of common stock at an exercise price of $42.45 per share, then sold 10,000 shares of common stock at a price of $98 per share. The filing states this activity was carried out under a Rule 10b5-1 trading plan adopted on December 16, 2024, indicating it was pre‑scheduled. Following these transactions, Anders beneficially owned 108,065 shares of common stock, which includes 42,338 restricted stock units, and held 15,900 stock options directly.
A holder of RVMD common stock has filed a Rule 144 notice for a planned sale of 75,000 common shares through Morgan Stanley Smith Barney LLC on or about 01/07/2026 on the NASDAQ market. The shares to be sold have an aggregate market value of 5988750.00, based on the figures provided, compared with 193,319,805 common shares outstanding. The securities were acquired the same day, 01/07/2026, via an exercise of stock options from the issuer for cash. Over the prior three months, the person named Margaret A Horn sold 4,847 common shares on 12/16/2025 for gross proceeds of 372333.45.
An insider of RVMD, Jack Lee Anders, filed a notice under Rule 144 to sell 10,000 shares of common stock through Morgan Stanley Smith Barney LLC, with an aggregate market value of
Over the prior three months, Anders sold additional common shares, including 3,104 shares on 12/16/2025 for gross proceeds of
Revolution Medicines, Inc. reported an insider transaction by its General Counsel, who filed a Form 4 as a single reporting person. On 12/16/2025, the officer sold 2,688 shares of common stock at a price of $76.8169 per share. After this sale, the reporting person beneficially owned 47,884 shares.
The transaction was made pursuant to a pre-arranged Rule 10b5-1 instruction letter adopted on May 31, 2023, to satisfy tax withholding obligations upon vesting of restricted stock units (RSUs) after July 15, 2023. The reported holdings include 147 shares acquired under the company’s Employee Stock Purchase Plan on November 30, 2025, and 38,769 RSUs, which represent additional equity that may be delivered over time as they vest.
Revolution Medicines, Inc. insider transaction: President and Chief Executive Officer Mark A. Goldsmith, who is also a director, reported selling 15,394 shares of Revolution Medicines common stock on 12/16/2025 at a price of $76.8173 per share. The sale was made under a Rule 10b5-1 instruction letter adopted on May 31, 2023 to cover tax withholding obligations arising from the vesting of restricted stock units.
After this transaction, Goldsmith beneficially owns 232,469 shares directly, which includes 168,763 restricted stock units. He also holds additional indirect interests through trusts, including 67,424 shares held by the Jonathan Goldsmith Revocable Trust, 67,424 shares held by the Rebecca Goldsmith Revocable Trust, and 570,050 shares held by the Mark A. Goldsmith and Anne E. Midler 2002 Revocable Living Trust.
Revolution Medicines, Inc. reported that officer Stephen Michael Kelsey, President of Research and Development, disposed of 5,447 shares of common stock on 12/16/2025 at a price of $76.8172 per share. This sale was coded as an "S" transaction and was made under a Rule 10b5-1 instruction letter adopted on May 31, 2023 to cover tax withholding obligations related to restricted stock unit (RSU) vesting after July 15, 2023. Following this transaction, Kelsey beneficially owned 278,600 shares of common stock, including 73,576 RSUs.
Revolution Medicines, Inc. Chief Operating Officer Margaret Horn reported a sale of company stock in an insider filing. On 12/16/2025, she disposed of 4,847 shares of common stock at a price of $76.8173 per share. The filing states this transaction was executed under a pre-arranged Rule 10b5-1 instruction letter adopted on May 31, 2023, to cover tax withholding obligations triggered by the vesting of restricted stock units.
After this transaction, Horn beneficially owned 141,053 shares of Revolution Medicines common stock, which includes 61,226 restricted stock units. The form indicates the holdings are directly owned.
FAQ
What is the current stock price of Revolution Medicines (RVMD)?
What is the market cap of Revolution Medicines (RVMD)?
